Plus   Neg

Axsome Therapeutics Inc. (AXSM) Is Surging On Study Results

Axsome Therapeutics Inc. (AXSM) announced Monday morning that its Phase 2 study of AXS-05 met the primary endpoint and significantly improved symptoms of depression.

Axsome Therapeutics has gapped open sharply higher this morning and is now up 3.81 at $6.44 on above average volume. The stock has leaped to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT